Header Logo

Connection

JOSEPH JANKOVIC to Young Adult

Back to Details
This is a "connection" page, showing publications JOSEPH JANKOVIC has written about Young Adult.
JOSEPH JANKOVIC
Connection Strength
0.956
Young Adult
  1. Axial tics in Tourette syndrome and chronic tic disorders. J Neurol. 2024 Nov; 271(11):7232-7238.
    View in: PubMed
    Score: 0.087
  2. Juvenile parkinsonism: Differential diagnosis, genetics, and treatment. Parkinsonism Relat Disord. 2019 10; 67:74-89.
    View in: PubMed
    Score: 0.060
  3. Young-onset Parkinson's disease: Its unique features and their impact on quality of life. Parkinsonism Relat Disord. 2019 08; 65:39-48.
    View in: PubMed
    Score: 0.060
  4. Real-World Experience With VMAT2 Inhibitors. Clin Neuropharmacol. 2019 Mar/Apr; 42(2):37-41.
    View in: PubMed
    Score: 0.059
  5. Botulinum Toxin for the Treatment of Hand Tremor. Toxins (Basel). 2018 07 19; 10(7).
    View in: PubMed
    Score: 0.056
  6. Cervical dystonia and substance abuse. J Neurol. 2018 Apr; 265(4):970-975.
    View in: PubMed
    Score: 0.055
  7. Apraclonidine in the treatment of ptosis. J Neurol Sci. 2017 May 15; 376:129-132.
    View in: PubMed
    Score: 0.051
  8. Examiner manoeuvres 'sensory tricks' in functional (psychogenic) movement disorders. J Neurol Neurosurg Psychiatry. 2017 05; 88(5):453-455.
    View in: PubMed
    Score: 0.051
  9. Psychogenic Ophthalmologic Movement Disorders. J Neuropsychiatry Clin Neurosci. 2016; 28(3):195-8.
    View in: PubMed
    Score: 0.047
  10. Dopa-responsive dystonia--clinical and genetic heterogeneity. Nat Rev Neurol. 2015 Jul; 11(7):414-24.
    View in: PubMed
    Score: 0.046
  11. Stiff-person syndrome: insights into a complex autoimmune disorder. J Neurol Neurosurg Psychiatry. 2015 Aug; 86(8):840-8.
    View in: PubMed
    Score: 0.044
  12. The clinical features of psychogenic movement disorders resembling tics. J Neurol Neurosurg Psychiatry. 2014 May; 85(5):573-5.
    View in: PubMed
    Score: 0.041
  13. Long-term efficacy and safety of fluphenazine in patients with Tourette syndrome. Mov Disord. 2014 Jan; 29(1):126-30.
    View in: PubMed
    Score: 0.041
  14. Amplitude fluctuations in essential tremor. Parkinsonism Relat Disord. 2012 Aug; 18(7):859-63.
    View in: PubMed
    Score: 0.037
  15. Motor-phonic tic mimicking essential palatal myoclonus. Mov Disord. 2009 Oct 15; 24(13):2030-2.
    View in: PubMed
    Score: 0.031
  16. A randomised, double-blind, placebo-controlled study of topiramate in the treatment of Tourette syndrome. J Neurol Neurosurg Psychiatry. 2010 Jan; 81(1):70-3.
    View in: PubMed
    Score: 0.030
  17. Hemidystonia-hemiatrophy syndrome. Mov Disord. 2009 Mar 15; 24(4):583-9.
    View in: PubMed
    Score: 0.030
  18. Efficacy and Safety of DaxibotulinumtoxinA for Injection in Cervical Dystonia: ASPEN-1 Phase 3 Randomized Controlled Trial. Neurology. 2024 02 27; 102(4):e208091.
    View in: PubMed
    Score: 0.021
  19. Dystonia and Tremor: A Cross-Sectional Study of the Dystonia Coalition Cohort. Neurology. 2021 01 26; 96(4):e563-e574.
    View in: PubMed
    Score: 0.016
  20. Parkinson's disease age at onset genome-wide association study: Defining heritability, genetic loci, and a-synuclein mechanisms. Mov Disord. 2019 06; 34(6):866-875.
    View in: PubMed
    Score: 0.015
  21. Neurohistopathological findings at the electrode-tissue interface in long-term deep brain stimulation: systematic literature review, case report, and assessment of stimulation threshold safety. Neuromodulation. 2014 Jul; 17(5):405-18; discussion 418.
    View in: PubMed
    Score: 0.011
  22. Mutation screening of the HTR2B gene in patients with Tourette syndrome. Neurosci Lett. 2012 Sep 27; 526(2):150-3.
    View in: PubMed
    Score: 0.009
  23. Deep brain stimulation hardware complications in patients with movement disorders: risk factors and clinical correlations. Stereotact Funct Neurosurg. 2012; 90(5):300-6.
    View in: PubMed
    Score: 0.009
  24. Human T-cell responses to botulinum neurotoxin. Responses in vitro of lymphocytes from patients with cervical dystonia and/or other movement disorders treated with BoNT/A or BoNT/B. J Neuroimmunol. 2011 Dec 15; 240-241:121-8.
    View in: PubMed
    Score: 0.009
  25. Human T-cell responses to botulinum neurotoxin: proliferative responses in vitro of lymphocytes from botulinum neurotoxin A-treated movement disorder patients. J Neuroimmunol. 2011 Aug 15; 237(1-2):66-72.
    View in: PubMed
    Score: 0.009
  26. Significance and confounders of peripheral DJ-1 and alpha-synuclein in Parkinson's disease. Neurosci Lett. 2010 Aug 09; 480(1):78-82.
    View in: PubMed
    Score: 0.008
  27. Multiple LRRK2 variants modulate risk of Parkinson disease: a Chinese multicenter study. Hum Mutat. 2010 May; 31(5):561-8.
    View in: PubMed
    Score: 0.008
  28. Long-term efficacy and safety of botulinum toxin type A (Dysport) in cervical dystonia. Parkinsonism Relat Disord. 2010 Jun; 16(5):316-23.
    View in: PubMed
    Score: 0.008
  29. DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease. Brain. 2010 Mar; 133(Pt 3):713-26.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.